Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
XOMA Corp
NASDAQ XOMAP
Data sourced from
and
and
XOMA Corp Accumulated Other Comprehensive Income 3 year CAGR for the year ending December 31, 2023
XOMA Corp Accumulated Other Comprehensive Income 3 year CAGR is NA for the year ending December 31, 2023. Accumulated Other Comprehensive Income is the cumulative gains or losses from non-owner sources that have not yet been recognized in the income statement. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: XOMAP
| CEO | - |
| IPO Date | Dec. 16, 2020 |
| Location | United States |
| Headquarters | 2200 Powell Street, EmeryVille, CA, United States, 94608 |
| Employees | 13 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
Key trends
Similar companies
XOMA Corporation
NA
NA
StockViz Staff
September 19, 2024
Any question? Send us an email